| 摘要 |
The use of agents capable of inhibiting the function of bone morphogenetic protein (BMP), particularly BMP-2, BMP-6 or BMP-7, in the treatment of spondyloarthropathies (SpA), or enthesitis in SpA. The agents may be antagonists, ligands, antibodies, antisense molecules or ribozymes. Preferably the agent is an antagonist of BMP, such as noggin, chordin, follistatin or gremlins. The diseases treated may include ankylosing spondylitis, psoriatic, enteropathic, or reactive arthritis, Reiter's arthritis or arthritis associated with inflammatory bowel disease. |
